New antibody targets Hard-to-Treat skin cancer in first human trial
NCT ID NCT07213882
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called DT-7012 for people with a rare type of skin lymphoma (CTCL) that has not responded to other treatments. The drug is an antibody designed to find and kill cancer cells in the skin and boost the immune system. About 30 adults with advanced mycosis fungoides or Sézary syndrome will receive the drug to see if it is safe and what dose works best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart a rare skin cancer?
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers
- Supercharged immune cells aim to stop lymphoma comeback
- Massive T-Cell lymphoma database aims to unlock new insights